News und Analysen
EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS-News: New legal form: VERBIO Vereinigte BioEnergie AG has been converted into Verbio SE
EQS-News: New legal form: VERBIO Vereinigte BioEnergie AG has been converted into Verbio SE
EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: VERBIO AG: Q1 2023/24: Forecast confirmed
EQS-News: VERBIO AG: Q1 2023/24: Forecast confirmed
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: VERBIO Vereinigte BioEnergie AG: VERBIO Capital Markets Day 2023: Global growth and value added continue
EQS-News: VERBIO Vereinigte BioEnergie AG: VERBIO Capital Markets Day 2023: Global growth and value added continue
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-News: VERBIO Vereinigte BioEnergie AG: FY 2022/2023: Second-best results in the history of VERBIO
EQS-News: VERBIO Vereinigte BioEnergie AG: FY 2022/2023: Second-best results in the history of VERBIO
EQS-Adhoc: VERBIO Vereinigte BioEnergie AG: VERBIO forecasts EBITDA of EUR 200 million to EUR 250 million for the financial year 2023/24.
EQS-Adhoc: VERBIO Vereinigte BioEnergie AG: VERBIO forecasts EBITDA of EUR 200 million to EUR 250 million for the financial year 2023/24.
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: VERBIO Vereinigte BioEnergie AG: Virtual extraordinary general meeting approves a resolution for conversion into an SE (Societas Europaea)
EQS-News: VERBIO Vereinigte BioEnergie AG: Virtual extraordinary general meeting approves a resolution for conversion into an SE (Societas Europaea)
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler